Medicare policy for cellular and/or tissue-based products (CTPs, sometimes called “skin substitutes”) is undergoing its most consequential reset in years, with particular implications for every site of service where diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) are treated. Below is an overview of what wound care clinicians need to know now about the 2026 Physician Fee Schedule (PFS) payment change, the status of Local Coverage Determinations (LCDs), and how Centers for Medicare and Medicaid Services’ (CMS) new WISeR model interacts with CTP utilization and documentation.^1-5

2026 PFS: CTPs shift to incident-to supplies with a standardized rate

Until 2025, most CTPs furnished in the office were paid under the Part B drug/biologic methodology: average sales price (ASP)-based, product-specific payment limits. In the Calendar Year (CY) 2026 PFS Final Rule, CMS finalized a different approach: when a CTP is applied as part of a covered procedure, the product will be paid as an incident-to supply rather than as a separately paid “biologic,” aligning policy across settings (physician office and hospital outpatient department) and across FDA regulatory categories (361 HCT/Ps, 510(k) devices, and PMA products).¹ CMS also finalized, for 2026 only, a single national rate calibrated to the highest average across those categories (approximately $127.28 per sq cm, subject to standard geographic adjustments), with an explicit intent to propose category-differentiated rates in future rulemaking.^1-2 In practical terms, this replaces product-specific ASP+6% rates with a uniform, procedure-linked supply payment; tightening price dispersion, potentially simplifying claims, and putting more emphasis on correct coding and documentation of medical necessity.^1-2 

LCD status: highly restrictive 2024 MAC policies withdrawn before go-live

In late 2024, all Medicare Administrative Contractors (MACs) finalized substantially harmonized, but still individual, LCDs for DFU/VLU that would have narrowed the list of covered CTPs and layered in more prescriptive clinical criteria. Many programs spent 2025 preparing for a January 1, 2026, effective date. On December 24, 2025, however, CMS announced that the Medicare Administrative Contractors (MACs) were withdrawing those LCDs “effective immediately,” halting their implementation.³ As of early 2026, there is therefore no new nationwide LCD regime in force; coverage reverts to existing local policies and general Medicare requirements until/unless the MACs re-issue coverage criteria. Care teams should continue to verify local policy articles and LCDs for their MAC and monitor for updates, but the widely anticipated 2026 LCD restrictions did not take effect.³ 

WISeR: a new CMS Innovation Center model that explicitly names skin and tissue substitutes

Launched by CMS in June 2025, the Wasteful and Inappropriate Service Reduction (WISeR) model pilots technology-enabled prior authorization and pre-payment review to curb low-value or inappropriately used services in Original Medicare across select states only. The model’s initial target list includes skin and tissue substitutes, along with other items and procedures often flagged for excessive variation. WISeR does not change statutory coverage rules; rather, it changes how some requests/claims are reviewed in participating geographies, with clinician reviewers and performance-based payments to model participants tied to reduced inappropriate utilization and faster, more consistent decisions. For wound care teams, the operational consequence is straightforward: expect higher scrutiny on indication, timing (eg, after an adequate trial of standard care), frequency/quantity, and response-to-therapy documentation for CTPs where WISeR is active and in MAC locations that have current LCDs in effect.⁴ 

What this means for daily practice in 2026.

1. Coding and units matter more than ever. The flat supply rate makes correct Healthcare Common Procedure Coding System (HCPCS) application codes, measurements, wastage awareness, and site-of-service modifiers critical to accurate payment. Teams should re-validate chargemasters, electronic health record (EHR) order sets, and superbills against the 2026 coding crosswalks referenced in the PFS material.^1-2 
2. Product selection should balance clinical fit with rate economics. With a uniform payment in 2026, products with acquisition costs well above the standardized rate will create margin pressure in certain sites of service. This shifts some selection calculus toward products whose clinical value can be achieved at or below the rate without compromising outcomes.¹ 
3. Documentation must reflect medical necessity and response. Even with the LCD withdrawal, the WISeR model’s focus on “appropriate use” of targeted services raises the bar on recording standard of care (SOC) failure, wound characteristics (size, depth, duration, infection control), frequency/intervals between applications, and objective response across episodes.⁴ 
4. Keep watching the LCD space. The December 2025 withdrawal doesn’t preclude future LCDs. If MACs relaunch coverage criteria, expect more consistent evidentiary thresholds across jurisdictions, potentially tied to product-level evidence and head-to-head data.³ 

Bottom line for wound programs

For CY 2026, the key reimbursement pivot is payment method (standardized, incident-to supply under the PFS) rather than a new national coverage rule, because the anticipated cross-MAC LCDs were pulled back before launch.^1,3 The WISeR model adds a complex oversight layer in select regions that spotlights CTPs and puts a premium on meticulous documentation and consistent clinical pathways.⁴ In this environment, programs that hard-wire SOC prerequisites, product-specific checklists, and objective response tracking into their workflows could be better positioned to preserve access for appropriate patients, withstand scrutiny, and navigate the economics of the 2026 rate while CMS considers category-specific refinements for future years.^1-2,4

References

1.        Centers for Medicare & Medicaid Services (CMS). CY 2026 Medicare Physician Fee Schedule final rule (CMS-1832-F): section “Skin substitutes” (standardized incident-to supply payment; temporary single rate for 2026; cross-setting alignment). Published October 31, 2025. Available at: https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare…

2.        Federal Register. Medicare and Medicaid programs; CY 2026 payment policies under the Physician Fee Schedule and other changes to Part B payment policies (final rule). Published November 5, 2025. Available at: https://www.federalregister.gov/documents/2025/11/05/2025-19787/medicar…

3.        Centers for Medicare & Medicaid Services (CMS). Final local coverage determinations (LCDs) for certain skin substitutes withdrawn. Published December 24, 2025. Available at: https://www.cms.gov/newsroom/fact-sheets/upcoming-update-final-local-co…

4.        Centers for Medicare & Medicaid Services (CMS). CMS launches new model to target wasteful, inappropriate services in Original Medicare (WISeR). Press release. Published June 27, 2025. Available at: https://www.cms.gov/newsroom/press-releases/cms-launches-new-model-targ…

5.        Bechelli J, Desai S, et al. Wound care—Part II: Tissue-engineered skin substitutes and other advanced biologics. J Am Acad Dermatol. 2025. Available at: https://www.jaad.org/article/S0190-9622%2825%2902375-8/fulltext